These results suggest that cfDNA testing may be a quick and easy alternative to identify BRAF mutations in patients for whom an archival tumor tissue sample may not be available in sufficient quality to allow for a retesting population, so they can benefit from the early initiation of BRAF-targeted therapy. The gene discussed is BRAF; the disease is neoplasm.